DEALS: Actavis buys Amide Pharmaceuticals

DEALS

WHO

WITH

WHAT

SCOOP

Bionomics

Iliad Chemicals

$9M buyout

The deal is intended to help beef up Bionomics' pipeline toward its goal of having two Phase II products and five preclinical programs by 2008.

Actavis

Amide Pharmaceuticals

$500M buyout

The buyout gives Actavis a much bigger beachhead in the American generics market, making it easier to sell generic drugs and introduce new pharmaceuticals.  

Cephalon

Salmedix

$160M buyout

Researchers at Salmedix have been testing Treanda as both a treatment for non-Hodgkin's lymphoma for patients who have not responded to Rituxan and a complement to Rituxan.

Invitrogen

Caltag Laboratories

$20M buyout

The deal adds Caltag's library of antibodies to Invitrogen's rapidly expanding stockpile.

BioXell

Merck

$150M drug development pact

Merck has agreed to pay up to that amount to develop the company's lead product, TREM-1, which targets a receptor on specific immune cells.

Lexicon Genetics

Organon Labs

Drug collaboration

The research work will concentrate on 300 genes that encode therapeutic antibodies and proteins.